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Objectives: Taiwan’s National Health Insurance (NHI) has encouraged physicians to use “chronic medication
prescriptions” for patients with stable chronic diseases since 1995. Patients are allowed to refill such prescriptions at
community pharmacies for a maximum of three months’ supply of medications without revisiting the doctor. In
2006, NHI initiated strategies targeting the public, doctors, and healthcare facilities to enhance the overall rate of
chronic medication prescriptions, aiming to achieve 30% by 2010. We examined prescribing and dispensing of oral
antidiabetic drugs from 2001 to 2010, before and after the start of the promotion strategies for chronic medication
prescriptions in 2006.
Methods: Using outpatient care data from the NHI database and the interrupted time series design, we analyzed
changes in rate of chronic medication prescriptions, share of prescriptions filled at community pharmacies, and
share of reimbursed expenditures accounted by community pharmacies.
Results: During 2001-2010, the rate of chronic medication prescriptions for diabetes increased steadily by about 3%
per year (from 3.5% to 26.2%). Three years after the promotion strategies, there was a non-significant reduction of
8.7% (95% confidence interval [CI]: -17.35%, 0.05%) in the rate of chronic medication prescriptions but increases in
prescription refills at community pharmacies and associated reimbursed expenditures: 12.8% (95% C.I.:1.66%,
23.98%) and 15.8% (95% C.I.: -1.35%, 33.02%) respectively.
Conclusions: While rate of chronic medication prescriptions was not significantly affected by the 2006 promotion
strategy, shares of prescriptions refilled at community pharmacies and associated expenditures increased slightly
but significantly.
Keywords: Interrupted time series, Oral antidiabetic medications, Chronic medication prescriptions, TaiwanIntroduction
Diabetes mellitus has become a global epidemic [1-3]
and is a major and growing cause of morbidity and mor-
tality in most countries [4-7]. More than 346 million
people worldwide (~7.7%) [8-10] and about 1.47 million
people in Taiwan (~4.5%) [11] were estimated to have
diabetes in 2010. The prevalence of type 2 diabetes has* Correspondence: jasonhsu@mail.ncku.edu.tw
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unless otherwise stated.risen steeply. Main reasons for the increasing prevalence
of type 2 diabetes (~90% of diabetes mellitus) include a
more sedentary lifestyle, increased rates of obesity, im-
proved diagnosis, longer life expectancy and aging popu-
lations [3,5,7,12].
Oral hypoglycemic medications are the mainstay of
treating type 2 diabetes. New oral hypoglycemic medi-
cations – thiazolidinediones and dipeptidyl peptidase
inhibitors – have become available over the last decade.
Given the growing prevalence of type 2 diabetes, the avail-
ability of new but more expensive medications is likely tois is an Open Access article distributed under the terms of the Creative
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and the economic burden for public and private health
care payers [6,13].
Understanding prescribing patterns can inform the de-
velopment of interventions to promote appropriate use
of medicines. Studies have reported the utilization of an-
tidiabetic medications over time in the US [14,15], the
UK [5,7,16], Italy [3], Germany [6,17], France [2], and
Hungary [18]. In Taiwan, Chiang et al. [19] reported pre-
scribing patterns of oral antidiabetic drugs from 1997 to
2003. However, no studies have reported recent trends in
utilization of oral antidiabetic medications in Taiwan.
Further, little is known about health policy impacts on
access to oral antidiabetic agents.
Since 1995, Taiwan’s National Health Insurance (NHI)
has encouraged physicians to use “chronic medication
prescriptions” [20] for patients with stable chronic dis-
eases. Special prescription forms can be used to indicate
that prescribers allow prescriptions to be refilled once
a month for two times for a total of three months’
supply of medications instead of a month’s supply only
[21]. Using such prescriptions, patients can refill their
prescription at insurance-contracted community phar-
macies of their choice without revisiting a doctor’s
office [21]. Community pharmacies contracted with NHI
have the following key characteristics: (i) they are finan-
cially independent from any hospitals or clinics, but
may collaborate with primary-care physicians; [22]
and (ii) they can sell over-the-counter drugs, and dis-
pense prescription drugs for patients presenting prescrip-
tions from any hospitals or clinics (including chronic
medication prescriptions) and be reimbursed by NHI
(in contrast, hospital pharmacies can only dispense
prescriptions from their related hospitals or clinics)
[23]. The objectives of the promotion strategies for
chronic medication prescriptions are to reduce unnecessary
outpatient services and related expenses, including
outpatient registration fees, medication copayments,
and traveling expenses, and to enhance more convenient
access to medicines for treatment of chronic disease for
clinically stable patients.
In May 2006 Taiwan’s NHI initiated five-year strategies
to promote the use of chronic medication prescriptions.
The strategies involved efforts to: (1) continuously pro-
mote to patients the benefits of using chronic medication
prescriptions through patient education; (2) regularly
report rates of chronic medication prescriptions by
healthcare institutions on the National Health Insurance
Administration’s website for patients’ reference; (3) set
the target rates of chronic medication prescriptions
by end of 2006 (all healthcare institutions 15%; med-
ical centers 24%; regional hospitals 14%; local hospi-
tals 9%; and clinics 13%); and (4) aim to increase the
overall rate of chronic medication prescriptions by 4%per year for all healthcare institutions and reach an
average rate of 30% by 2010 [24].
The purpose of this study was to examine rates of
chronic medication prescriptions and shares of prescrip-
tion fills and reimbursed expenditures by hospitals vs.
community pharmacies from 2001 to 2010, before and
after the start of five-year promotion strategies in 2006.
Our study focused on oral antidiabetic agents, which are




This study used claims data from Taiwan’s National
Health Insurance Research Database (NHIRD). The data-
base includes information from a nationwide, mandatory-
enrollment and single-payer healthcare system created in
1995. Nearly all of the Taiwanese population (around 23
million residents) is enrolled and this system contracts
with 97% of hospitals and clinics throughout the country
[25]. The NHI covers a wide range of prescription medi-
cines, and inpatient and outpatient medical services [26].
We used claims data for outpatient care related to dia-
betes (International Classification of Diseases, 9th edition,
code 250.xx) from January 2001 to December 2010 ex-
tracted from NHIRD. For each prescription claimed, re-
cords actually indicate if the prescription used the
“chronic medication prescription form”, representing that
physicians allowed medications to be refilled at commu-
nity pharmacies.
Drugs of interest
Using the Anatomical Therapeutic Chemical classification
system of the World Health Organization, we grouped
oral hypoglycemic drugs into biguanides, sulfonylureas,
alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl
peptidase 4 inhibitors, and others (e.g., guar gum, repagli-
nide, nateglinide). Our analysis focused on the first five
classes because they accounted for 86.4%-99.2% of
utilization and 93.3%-97.2% of expenditures.
Outcome measures
To examine effects of the 2006 promotion strategies, we
measured quarterly rates of chronic medication prescrip-
tions for diabetes, defined as annual number of chronic
medication prescriptions for diabetes divided by annual
number of diabetic outpatient visits. This indicates up-
take of chronic medication prescriptions by physicians
(physician prescribing behavior). We also calculated the
quarterly and yearly shares of all antidiabetic prescrip-
tions refilled at community pharmacies. This is defined
as aggregated annual prescription volume in DDDs for
diabetes filled at community pharmacies divided by ag-
gregated annual prescription volume in DDDs filled at
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patients’ use of community pharmacies over time (patient
dispensing/refilling behavior). Similarly we calculated
shares of reimbursed expenditures for antidiabetic pre-
scriptions accounted by community pharmacies (aggregated
annual reimbursed expenditures accounted by community
pharmacies divided by aggregated annual reimbursed ex-
penditures accounted by both hospital and community
pharmacies). We calculated the above measures for both
overall and each class of antidiabetic agents.
To provide the context of utilization patterns of antidia-
betic medications in Taiwan, we calculated quarterly and
yearly prescription volume per patient and government-
reimbursed costs per patient. Annual prescription volume
per patient was defined as aggregated annual prescription
volume in daily defined doses (DDDs) divided by annual
number of diabetic patients. Similarly, annual government-
reimbursed costs per patient was defined as aggregated
annual expenditure of prescriptions for oral antidiabetic
drugs divided by annual number of diabetic patients. We
calculated these for each class of antidiabetic agents and
for all oral antidiabetic drugs.
Statistical analysis
We used the interrupted time series design [27], a strong
quasi-experimental method, to examine impacts of the
2006 promotion strategies on rates of chronic medication
prescriptions, proportion of prescriptions refilled at commu-
nity pharmacies, and proportion of expenditures accounted
by community pharmacies. We used segmented linear re-
gression models to estimate post–policy changes in both
the level and trend of these study outcomes [28-31]. Using
baseline trends, we projected rates over time with the as-
sumption that the baseline trend reflected what would
have happened without the implementation of the promo-
tion strategies. The basic model included terms to esti-
mate the baseline level for each outcome (intercept),
baseline trend (slope), changes in the level immediately
after policy implementation, and changes in trend after
the policy [27,32]. Our models controlled for autocorrel-
ation [33]. To identify the most parsimonious models, we
used backward elimination and excluded non-significant
terms (P > 0.05). To summarize results in a single metric,
we estimated absolute and relative changes (with 95% con-
fidence intervals, CI) [34] in outcomes at both 1 year and
3 years following the 2006 promotion strategies compared
to projected rates. All analyses were carried out with SAS
software, Version 9.3 (SAS Institute, Cary, NC).
Results
Utilization of oral antidiabetic medications over time
During the 10-year study period, the estimated number
of patients with type 2 diabetes in Taiwan increased
from 527,045 in 2001 to 1,025,646 in 2010, an averagerate of 10.5% increase per year, while the Taiwanese
population increased from 22.4 million in 2001 to 23.0
million in 2010, an average annual rate of 0.3% [35].
The volume of oral antidiabetic drugs prescribed in-
creased from 585.9 DDDs per patient per year in 2001
to 650.5 DDDs per patient per year in 2004, but de-
creased slightly after 2007 to 635.6 DDDs per patient
per year in 2010. Similarly, expenditures on oral anti-
diabetic drugs increased from US$162.8 per patient per
year in 2001 to US$241.64 per patient per year in 2004,
then slightly decreased after 2006 to US$195.34 per pa-
tient per year in 2010 (see Table 1).
By drug class, sulfonylureas and biguanides, which are
generally recommended as first-line therapies, domi-
nated the Taiwan market for diabetic management over
the last decade. The use of biguanides remained steady
(averaging 136.6 DDDs per patient per year during the
period 2003 to 2010). However, sulfonylureas gradually
decreased from 458.5 DDDs per patient per year in 2003 to
325.4 DDDs per patient per year in 2010, while use of
newer classes of antidiabetic medications (alpha-glucosidase
inhibitors, thiazolidinediones, dipeptidyl peptidase 4
inhibitors) increased. Figure 1 shows the volumes of oral
antidiabetic drugs refilled by hospital and community
pharmacies over time separately. The volume refilled by
community pharmacies increased steadily for each class of
medications during this period.
Effects of strategies on rates of chronic medication
prescriptions
Table 2 presents the rate of chronic medication prescrip-
tions, share of prescriptions refilled at community phar-
macies, and share of reimbursed expenditures accounted
by community pharmacies annually over time. During
2001-2010, the overall rate of chronic medication prescrip-
tions (3.54%-26.24%), the share of prescriptions refilled at
community pharmacies (3.67%-31.30%), and the share of
reimbursed diabetes medication expenditures accounted
by community pharmacies (3.36%-32.35%) increased stead-
ily at an average rate of around 3% per year. Classes of
medications showed similar growth rates for share of pre-
scriptions refilled at community pharmacies and share of
reimbursed expenditures accounted by community phar-
macies during the study period. Examining share of pre-
scriptions refilled at community pharmacies and share of
reimbursed expenditures accounted by community phar-
macies revealed similar findings.
Table 3 details parameter estimates from segmented re-
gression models of changes in outcomes following the pro-
motion strategies. Figure 2 shows the changes in rate of
chronic medication prescriptions and the share of prescrip-
tions refilled at community pharmacies over time.
The rate of chronic medication prescriptions gradually
rose from 3% in the first quarter of 2001 to 19% in the
Table 1 Population trends in use of oral antidiabetic drugs
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Overall
Patient Number 527,045 579,017 624,540 689,423 736,743 784,132 843,334 903,947 969,161 1,025,646
Volume/patient (DDDs)c. 585.94 613.85 640.25 650.54 652.36 651.68 653.71 637.1 630.16 635.59
Expenditure/patient (US$)d. 162.80 199.99 219.48 241.64 233.55 232.84 216.31 207.33 205.63 195.34
Subgroups by class
Volume/patient (DDDs)c.
Biguanides 125.11 127.77 129.51 133.68 137.99 141.71 144.18 144.81 143.07 138.19
Sulfonylureas 449.33 453.46 458.54 444.33 421.16 410.44 399.74 379.16 354.72 325.44
Alpha-glucosidase inhibitors 3.64 5.97 10.72 13.81 14.67 16.13 18.04 19.35 19.34 19.21
Thiazolidinediones 3.23 16.04 27.48 34.15 31.15 32.64 36.64 37.44 36.66 38.4
Dipeptidyl peptidase-4 inhibitors N/A b. N/A N/A N/A N/A N/A N/A N/A 10.17 27.40
Othersa. 4.63 10.61 14.00 24.56 47.38 51.12 55.12 56.35 66.21 85.93
Expenditure/patient (US$)d.
Biguanides 51.20 51.67 46.46 46.73 46.99 44.42 34.65 32.88 32.47 28.97
Sulfonylureas 94.38 98.10 95.10 98.36 96.40 94.07 85.00 81.35 74.84 59.13
Alpha-glucosidase inhibitors 4.94 7.41 12.46 15.81 16.52 17.87 18.54 18.45 17.39 15.06
Thiazolidinediones 7.70 33.85 53.87 66.64 60.65 62.64 64.40 60.83 55.67 48.42
Dipeptidyl peptidase-4 inhibitors N/A N/A N/A N/A N/A N/A N/A N/A 11.68 31.13
Othersa. 4.59 8.97 11.59 14.10 12.99 13.84 13.72 13.80 13.58 12.63
a. Others: guar gum, repaglinide, nateglinide, exenatide, liraglutide, mitiglinide.
b. N/A = not applicable.
c. Volume/patients (DDDs) = aggregated annual volume (DDDs) of prescription/annual number of diabetic patient.
d. Expenditure/patient (US$) = aggregated annual expenditure (US$) of prescription/annual number of diabetic patient.
Figure 1 Volume of oral antidiabetic drug prescriptions filled at hospitals and community pharmacies over time.
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Table 2 Rates of chronic medication prescriptionsa. and prescriptions filled at community pharmacies over time
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Overall
Rate of chronic medication prescriptions for diabetes (%)d. 3.54% 5.65% 9.40% 12.84% 15.77% 19.94% 23.13% 25.29% 26.55% 26.24%
Share of prescriptions filled at community pharmacies (%)e. 3.67% 5.52% 8.38% 10.40% 14.20% 16.68% 19.37% 23.46% 28.14% 31.30%
Share of reimbursed expenditures accounted by community
pharmacies (%)f.
3.36% 4.97% 7.11% 9.30% 13.71% 16.23% 19.51% 24.48% 29.22% 32.35%
Subgroups by class
Share of prescriptions filled at community pharmacies (%)e.
Biguanides 3.43% 5.31% 8.39% 10.44% 14.12% 16.73% 19.52% 23.32% 28.22% 31.66%
Sulfonylureas 4.01% 6.22% 9.59% 11.80% 15.58% 17.96% 20.17% 24.06% 28.42% 31.29%
Alpha-glucosidase inhibitors 0.94% 1.98% 3.17% 6.14% 10.27% 13.38% 17.06% 22.02% 27.48% 30.95%
Thiazolidinediones 1.21% 2.93% 4.66% 6.81% 11.23% 13.67% 18.18% 23.91% 29.23% 32.00%
Dipeptidyl peptidase-4 inhibitors N/A c. N/A N/A N/A N/A N/A N/A N/A 24.89% 30.32%
Othersb. 1.30% 1.51% 3.40% 5.30% 8.87% 11.99% 15.25% 20.12% 25.42% 28.59%
Share of reimbursed expenditures accounted by community pharmacies (%)f.
Biguanides 3.23% 5.07% 7.71% 9.98% 13.91% 16.92% 20.47% 24.77% 29.51% 32.91%
Sulfonylureas 3.85% 6.24% 9.49% 12.06% 16.61% 18.85% 21.13% 25.26% 29.73% 32.80%
Alpha-glucosidase inhibitors 0.75% 1.67% 2.78% 5.46% 9.47% 12.72% 16.47% 21.77% 27.63% 31.36%
Thiazolidinediones 1.12% 2.93% 4.29% 6.56% 11.18% 13.76% 18.62% 24.88% 30.28% 33.23%
Dipeptidyl peptidase-4 inhibitors N/A N/A N/A N/A N/A N/A N/A N/A 25.81% 31.13%
Othersb. 1.28% 1.38% 2.99% 5.11% 8.71% 11.88% 15.38% 20.97% 26.41% 29.80%
a. Chronic medication prescriptions allow prescriptions to be refilled once a month for two times for a total of three months’ supply of medications, without
repeat visits to a doctor’s office.
b. Others: guar gum, repaglinide, nateglinide, exenatide, liraglutide, mitiglinide.
c. N/A = not applicable.
d. Rate of chronic medication prescriptions for diabetes = annual number of chronic medication prescriptions for diabetes/annual number of diabetic
outpatient visits.
e. Share of prescriptions filled at community pharmacies = aggregated annual volume (DDDs) of prescription filled at community pharmacies/aggregated annual
volume (DDDs) of prescription filled at both hospital and community pharmacies.
f. Share of reimbursed expenditures accounted by community pharmacies = aggregated annual reimbursed expenditures accounted by community pharmacies/
aggregated annual reimbursed expenditures accounted by both hospital and community pharmacies.
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egies were implemented in the third quarter of 2006,
there was a small increase in level (3.12%, 95% CI:
1.19% ~ 5.05%) but a small reduction in trend (-0.46%
per quarter, 95% CI: -0.63% ~ 0.29%). Compared to
expected rates, these represented an increase of 6.08%
(95% CI: -3.62% ~ 15.78%) at 1 year post-policy but a
reduction of 8.65% (95% CI: -17.35% ~ 0.05%) at 3 years
post-policy.
The rate of prescriptions filled at community pharma-
cies gradually grew from 4% in the first quarter of 2001
to 16% in the second quarter of 2006. After the pro-
motion strategies, there was a small increase in trend
(0.24% per quarter, 95% CI: 0.05% ~ 0.43%), leading to
statistically significant increases of 5.49% (95% CI:
0.79% ~ 10.19%) at 1 year post-policy and 12.82% (95%
CI: 1.66% ~ 23.98%) at 3 years post-policy compared to ex-
pected rates.
Following the promotion strategies, reimbursed ex-
penditures accounted by community pharmacies were6.80% (95% CI: -0.45% ~ 14.05%) higher at 1 year post-
policy compared to expected rates, and 15.83% (95%
CI: -1.35% ~ 33.02%) higher than expected at 3 years
post-policy.
Discussion
This study examined the long-term effects of a policy
change in Taiwan to reduce costs and enhance manage-
ment of chronic diseases – the 2006 strategies to promote
chronic medication prescriptions – on physician’s pre-
scribing behavior (rate of chronic medication prescrip-
tions) and patient’s prescription refill behavior (share of
prescription refills at hospital pharmacies vs. community
pharmacies) for diabetes.
Between 2001 and 2010, the number of physician
encounters with patients treated for diabetes in Taiwan
increased almost two-fold, possibly reflecting better
access to care and better diagnosis of diabetes over time.
The annual volumes and expenditures of antidiabetic
medications per capita were relatively stable during this
Table 3 Estimated changes (with 95% confidence intervala.) in use of oral antidiabetic products following the 2006 five-year chronic medication prescriptions
promotion strategy




















































a. 95% CI = estimate +/- (1.96*se); All terms p < 0.05 retained in models.
b. Rate of chronic medication prescriptions for diabetes = annual number of chronic medication prescriptions for diabetes/annual number of diabetic outpatient visits.
c. Share of prescriptions filled at community pharmacies = aggregated annual volume (DDDs) of prescription filled at community pharmacies/aggregated annual volume (DDDs) of prescription filled at both hospital
and community pharmacies.
d. Share of reimbursed expenditures accounted by community pharmacies = aggregated annual reimbursed expenditures accounted by community pharmacies/aggregated annual reimbursed expenditures accounted




























Rate of chronic medication prescription for diabetes
Regression line (rate of chronic medication prescription for diabetes)
RFline2
Rate of prescriptions filled by community pharmacies
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Regression line
Promotion Strategies of Chronic 
Medication Prescription Policy 
Implementation 
Figure 2 Quarterly proportions of chronic medication prescriptions for diabetes and of prescriptions refilled at community pharmacies, 2001-2010.
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sulfonylureas and an increase in volume of biguanides
in Taiwan are consistent with the majority of existing
articles in several countries over similar time periods, in-
cluding the US [14], UK [16], France [2], Germany [6,17]
and Italy [3]. The launch of new medications, alpha-
glucosidase inhibitors and thiazolidinediones, provided
physicians and patients more choices for diabetes man-
agement. Trends in use of oral antidiabetic medications
from 2001 to 2010 may be influenced by several interven-
tions and events. Examples include the launch of new
medications, new guidelines, patent expires, introduction
of generic products, and changes in reimbursement-
related policies [30].
Our findings indicate that the rate of chronic medica-
tion prescriptions for diabetes rose steadily between
2001 and 2010. Since 1995, the Taiwan’s National Health
Insurance Administration has allowed use of chronic
medication prescription forms by doctors for patients
whose treatments for their chronic condition have stabi-
lized. Theoretically, increases in uptake of chronic medi-
cation prescriptions should benefit both patients and
physicians. Patients save time spent traveling to visit
physicians and waiting time in offices, and also reduce
their financial burdens for fees associated with visits to
doctors’ offices [36]. Physicians can spend more time with
patients whose condition is less stable, and thereby pos-
sibly improve quality of care. For the healthcare system,
the promotion strategies intended to reduce use of and
spending on non-essential medical services. While chronic
medication prescriptions may reduce physician visits and
thus physician-patient encounters and communications,
instead it may enhance communication between phar-
macists and patients. Previous studies found a positiveassociation between chronic medication prescriptions
and medication access and adherence, and thereby a bet-
ter control of chronic diseases [37,38].
Our longitudinal study showed that the rate of chronic
medication prescriptions for diabetes did not increase
appreciably following the 2006 promotion strategies. In
fact, our estimate at 3 years post-policy was a reduction
of 8.65%, and overall the rate fell slightly short of the tar-
get rate of 30%. This finding may not be surprising be-
cause the goal of chronic medication prescriptions was to
enhance the convenience of refilling prescriptions by pa-
tients with stable disease [37], and the growth in chronic
medication prescriptions was likely to slow down at some
point after reaching the majority of patients with stable
diabetes. Another possible explanation might be that
the rate of chronic medication prescriptions has already
reached the annual target rates; thus there was no need to
prescribe using chronic medication prescription forms.
Moreover, chronic medication prescriptions may reduce
physician incomes due to foregone visit fees.
Our measures of proportion of prescription refilled at
community pharmacies and associated expenditures in-
dicate patient refilling behavior. In contrast to rates of
chronic medication prescriptions, the share of prescrip-
tions refilled at community pharmacies not only grew be-
tween 2001 and 2006, it increased at a higher rate after
the promotion strategies. Patients appear to be increas-
ingly motivated to refill prescriptions at community phar-
macies. Possible benefits to patients include convenience,
reduced cost, and more time to consult pharmacists when
they fill a prescription at community pharmacies, which
might result in increased accuracy in taking medicine and
decreased occurrence of drug-induced side effects [39,40].
Given their increasing importance in filling prescriptions,
Hsu et al. Journal of Pharmaceutical Policy and Practice  (2015) 8:15 Page 8 of 9community pharmacists also have the potential to become
more actively involved in evaluating and tracking health
outcomes. These potential outcomes should be examined
in future studies.
The continually increasing share of reimbursed expen-
ditures accounted by community pharmacies may have
economic implications beyond what we examined. For
example, community pharmacies have likely gained in-
creased profits by dispensing more prescription medica-
tions. In contrast, the policy may have impacted hospital
pharmacies’ operating income and management strategies
due to a reduced number of prescription refills.
Many countries allow multiple times of prescription re-
fills at community pharmacies for patients with chronic
illnesses to enhance medication access and adherence, for
example, the US and Australia. However, despite allow-
ing multiple months of supply of medications, patient
cost-sharing has been a major factor associated with
poor medication access and adherence in the US [41].
Apart from economic pressures, medication related be-
liefs (e.g., perceived necessity) also influence patients’
medication use behavior [42]. In Australia where patient
cost-sharing is less of a concern, factors associated with
medication non-adherence include perceived treatment
inefficacy and unfavorable side effects [43]. Experiences in
other countries suggest that other interventions may need
to be combined with chronic medication prescriptions to
enhance medication access and adherence in Taiwan.
This study has several limitations. Our interrupted
time series design is robust to most threats to internal
validity; a possible limitation is a co-intervention (an
intervention that occurred at the same time as the 2006
strategies and is related to the outcomes measured).
However, our review of policy documents showed no in-
terventions occurred at the same time as the promotion
strategies [44]. Second, our measures using insurance
claims data do not necessarily reflect actual drug con-
sumption by patients, similar to other studies using such
data sources. Third, we examined only oral antidiabetic
medications. Further studies are needed to understand
the effects of the 2006 promotion strategies on use of
medications for other chronic conditions such as hyper-
tension as well as medication adherence and patient sat-
isfaction with care. Fourth, we did not separately analyze
incident versus prevalent diabetes patients. The case-
mix of such populations may explain the small difference
in share of prescriptions filled at community pharmacies
between the different drug classes. Finally, we estimated
rates of chronic medication prescriptions using insur-
ance claims data rather than using electronic medical re-
cords data, thus may have underestimated the true rates
(sensitivity); however, our interrupted time series design
is able to detect changes in rate, adjusting for previous
trends; therefore, the change estimated would be in theright direction. Notwithstanding these limitations, this
study provided valuable insights into changes in physi-
cians’ prescribing behavior (uptake of chronic medication
prescriptions) and patients’ prescription refill behavior
(refills at hospitals vs. community pharmacies) for diabetes
care following the 2006 strategies to promote chronic
medication prescriptions in Taiwan.
Conclusion
With its aging population, rapid growth in the preva-
lence of chronic diseases is a challenge in Taiwan. Con-
tinued, affordable, equitable access to medications for
patients with stable chronic diseases plays an important
role in quality of care and prevention of complications
from diabetes. This study examined effects of NHI strat-
egies, implemented in 2006 for five years, to enhance ac-
cess to medications for chronic diseases. We focused on
medications for diabetes, a major chronic condition in
Taiwan. While rate of chronic medication prescriptions was
not significantly affected by the 2006 promotion strategies,
shares of prescriptions refilled at community pharmacies
and reimbursed expenditures accounted by community
pharmacies increased slightly but significantly.
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